Статті в журналах з теми "]+[628.4"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: ]+[628.4.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-18 статей у журналах для дослідження на тему "]+[628.4".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Dragojevic, Svetlana, Mladenko Vasiljevic, Ana Mitrovic, Radica Dunjic, Srdjan Dikic, and Fadil Canovic. "Hyperprolactinaemia as a potential cause of infertility." Jugoslovenska medicinska biohemija 22, no. 4 (2003): 335–39. http://dx.doi.org/10.2298/jmh0304335d.
Повний текст джерелаАнотація:
Establishing of hormonal disturbances is one of the most important steps in infertility studies. The aim of the study was to evaluate the importance frequency and treatment efficiency of hyperprolactinaemia in infertile patients. Eighty-seven infertile patients have been examined in this study. Matched samples of periph?eral blood were taken for hormonal analyses in the early follicular, periovulatory and midluteal phases of the cycle. Between the 4th and 7th day of the cycle ultrasonographic and haemodynamic examinations have been carried out at the ovarian and uterine levels. Hyperprolactinaemia was detected in 25 women, in which prolactin levels ranged 628.4-8000 mIU/L. We started dopamine agonists (bromocriptine/cabergoline) treatment individually dosaged. Menstrual cycle as well as prolactin levels restored in all patients 3 months after treatment initiation. Hyperprolactinaemia can derange fertility potential so its early and precise detection and adequate therapy are essential for restoration of regular menstrual cycle and successful infertility treatment.
2
McCoy, Andrew P., Dong Zhao, Teni Ladipo, Philip Agee, and Yunjeong Mo. "COMPARISON OF GREEN HOME ENERGY PERFORMANCE BETWEEN SIMULATION AND OBSERVATION: A CASE OF VIRGINIA, UNITED STATES." Journal of Green Building 13, no. 3 (June 2018): 70–88. http://dx.doi.org/10.3992/1943-4618.13.3.70.
Повний текст джерелаАнотація:
The United States has a long-term goal to reduce 50% of energy usage in buildings based on 2010 consumption levels. Home energy efficiency is often measured by laboratory experiments and computational simulation. Thus, there is little to no quantifiable evidence showing the extent of energy efficiency homes can achieve within the larger context of green building standards. The objective of this research is to identify actual home energy performance as an effect of green building technologies by comparing energy use from real-world observations and energy modeling. Results indicate a significant reduction of energy consumption at 43.7% per unit or 43.4% per square foot (i.e., 0.093 m2) and substantial financial savings at $628.4 per unit or $0.80 per square foot (i.e., $8.6 per m2) annually. Savings account for 2% of median annual household income or 46% of energy cost expenditures for an American home. Results also identify the construction type as a significant factor, yet building technology is not the only factor influencing a home's energy efficiency. The findings contribute to the body of knowledge in three aspects: (1) simulated energy usage is higher than actual energy usage; (2) energy modeling via simulation tools is particularly accurate for new construction; and (3) energy modeling, especially for existing buildings, is not accurate due to largely varying occupant behaviors.
3
Shoba, H., N. Rajeshwari, and G. Nagaraja. "A Study on Physico-Mechanical Properties of Onion Varieties Under Koppal District, (Karnataka)." Current Agriculture Research Journal 5, no. 3 (November 24, 2017): 381–86. http://dx.doi.org/10.12944/carj.5.3.18.
Повний текст джерелаАнотація:
The physico-mechanical properties of four popular cultivable onion varieties i.e., Ballari red, Arka kalyan, Satara (local verity), Kalasa (local variety) in Koppal (Karnataka)were studied to form an important database for designing of storage structures, cleaning, grading, sorting and harvesting equipments. The equatorial diameter of all size category Ballari red onion variety ranged from 4.01 to 8.35 cm, polar diameter ranged from3.82 to 6.62 cm and thickness of Ballari red onion variety ranged from 1.25 to 2.51 cm where as the lowest values of equatorial diameter was observed in Kalasa (local variety) i.e., 3.2 to 7.12 cm, polar diameter ranged from 2.89 to 5.12 cm and thickness from 1.22 to 2.01 cm, respectively. Shape index of three out of four was oval in shape. The geometric mean diameter (Dgm) and arthematic mean diameter (Dam) of large, medium and small size verities as Ballari red, Arka kalyan, Satara, Kalasa had 2.65 to 5.09, 2.5 to 4.58, 2.35 to 4.43 and 2.23 to 4.13 cm, respectively. The highest mean value of bulk density from 678.9 to 390.42 kg/cm3was observed in Ballari red onion followed by Arka kalyan of 662.7to 390.42 kg/cm3, Satara 628.4 to 390.23 kg/cm3, Kalasa 618.59 to 385.24 kg/cm3and highest mean value of angle of repose which was observed in Ballari red i.e, 37o (large size) and lowest was observed 20.90o in Kalasa (small size) variety.
4
Santana, Milana D. R., Brian Kliszczewicz, Franciele M. Vanderlei, Larissa R. L. Monteiro, Eli Carlos Martiniano, Yasmim M. de Moraes, Luana B. Mangueira, et al. "Autonomic responses induced by aerobic submaximal exercise in obese and overweight adolescents." Cardiology in the Young 29, no. 2 (February 2019): 169–73. http://dx.doi.org/10.1017/s1047951118002007.
Повний текст джерелаАнотація:
AbstractBackgroundGraded exercises tests are performed in adult populations; nonetheless, the use of this type of assessment is greatly understudied in overweight and obese adolescents.ObjectiveTo investigate heart rate autonomic responses to submaximal aerobic exercise in obese and overweight adolescents.MethodsWe recruited 40 adolescents divided into two groups: (1) overweight group comprising 10 boys and 10 girls between Z-score +1 and +2 and (2) obese group comprising 10 boys and 10 girls above Z-score >+2. Heart rate variability was analysed before (T1) and after exercise (T2–T4) on treadmill at a slope of 0%, with 70% of the maximal estimated heart rate (220 – age) for 20 minutes.ResultsHeart rate in the overweight group was: 93.2±10.52 bpm versus 120.8±13.49 bpm versus 94.6±11.65 bpm versus 93.0±9.23 bpm, and in the obese group was: 92.0±15.41 bpm versus 117.6±16.31 bpm versus 92.1±12.9 bpm versus 91.8±14.33 bpm. High frequency in the overweight group was: 640±633.1 ms2 versus 84±174.66 ms2 versus 603.5±655.31 ms2 versus 762.6±807.21 ms2, and in the obese group was: 628.4±779.81 ms2 versus 65.4±119.34 ms2 versus 506.2±482.70 ms2 versus 677.9±939.05 ms2; and root mean square of successive differences in the overweight group was: 37.9±18.81 ms versus 10.9±8.41 ms versus 32.8±24.07 ms versus 36.7±21.86 ms, and in the obese group was: 38.7±23.17 ms versus 11.5±8.62 ms versus 32.3±16.74 ms versus 37.3±24.21 ms. These values significantly changed during exercise compared with resting values in overweight and obese groups. Moreover, we also reported no significant difference of resting parasympathetic control of heart rate between obese and overweight adolescents.ConclusionThere was no significant difference of autonomic responses elicited by submaximal aerobic exercise between overweight and obese adolescents.
5
Legnani, Cristina, Benilde Cosmi, Giuliana Guazzaloca, Claudia Pancani, Sergio Coccheri, and Gualtiero Palareti. "Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped." Thrombosis and Haemostasis 87, no. 01 (2002): 7–12. http://dx.doi.org/10.1055/s-0037-1612936.
Повний текст джерелаАнотація:
SummaryIn some patients with previous venous thromboembolism (VTE) D-dimer levels (D-Dimer) tend to increase after oral anticoagulant therapy (OAT) is stopped. The aim of our study was to evaluate the predictive value of D-Dimer for the risk of VTE recurrence after OAT withdrawal. After a first episode of deep vein thrombosis (DVT) of the lower limbs and/or pulmonary embolism (PE), 396 patients (median age 67 years, 198 males) were followed from the day of OAT discontinuation for 21 months. D-dimer was measured on the day of OAT withdrawal (T1), 3-4 weeks (T2) and 3 months (+/− 10 days, T3) thereafter. The main outcome events of the study were: objectively documented recurrent DVT and/or PE. D-dimer was found to be increased in 15.5%, 40.3% and 46.2% of the patients at T1, T2 and T3, respectively. In 199 (50.2%) patients, D-dimer levels were elevated in at least one measurement. During a follow-up of 628.4 years, 40 recurrences were recorded (10.1% of patients; 6.4% patient-years of follow-up). D-dimer was increased in at least one measurement in 28 of these cases, but remained normal in 11 subjects (three of whom had recurrent events triggered by circumstantial factors, three with malignancyassociated factors) (in one subject D-dimer was not measured). The negative predictive value (NPV) of D-dimer was 95.6% (95% CI 91.6-98.1) at T3 and was even higher (96.7%; 95% CI 92.9-98.8) after exclusion of the six recurrences due to circumstantial factors. Only five idiopathic recurrences occurred in the 186 patients with consistently normal D-dimer. In conclusion, D-dimer has a high NPV for VTE recurrence when performed after OAT discontinuation.
6
AMUDHA, B., Y. E. A. RAJ, and S. B. THAMPI. "A statistical analysis of the differences between rainfall estimated by Chennai DWR and conventional rainfall data on monthly and seasonal scales during the Indian northeast monsoon season." MAUSAM 68, no. 2 (November 30, 2021): 261–78. http://dx.doi.org/10.54302/mausam.v68i2.629.
Повний текст джерелаАнотація:
The first Doppler Weather Radar (DWR) of India Meteorological Department has been functional at Chennai since the year 2002 providing various meteorological and hydrological products. Validation and statistical analysis of the DWR estimated rainfall (RERF, x) data with rain gauge measured rainfall (RGRF, y) of 34 land based stations located in the semi-circular land area within 100 km radius of Chennai DWR (CDLR100) has been performed for the northeast monsoon (NEM) season of October-November-December (OND) for the 12 year period 2002-13. The monthly and seasonal data have been derived using more than 1.42 lakh discrete daily RERF values available at a high resolution of 333 m × 333 m. The major objective of the study is to compute the various statistical parameters of x and y including the bias between them on monthly and seasonal scales and to draw certain inferences. The analysis was done using three different types of averaging. The yearly means of x and y for OND over CDLR100 manifested both positive and negative epochs with the mean absolute deviation (MAD) computed as 11 cm (17% of mean). The short term normals over CDLR100 are derived as 274.9, 262.6, 96.5 and 629.8 mm for x and 243.8, 254.6, 128.0 and 627.4 mm for y for October, November, December and OND yielding bias values of -31.2, -8.0, 31.5 and -2.4 mm respectively. The MAD for OND rainfall computed by pooling in all the 12 ´ 34 values is quite substantial at around 19 cm (30% of mean). The RF bias for each month / NEM season is shown to be independent of the geographical locations of the stations using correlation analysis. Based on the raw values of x and a proportional correction technique, estimated values of at the 1.42 lakh grid points of CDLR100 were derived yielding spatial means of 273.3, 262.2, 92.5 and 628.4 mm for x and 243.4, 254.3, 122.9 and 622.1 mm for for the three months and OND respectively. The importance of size of the bias in the correct interpretation of x has been discussed. A few suggestions based on certain statistical considerations have been putforth for decreasing the bias.
7
Pakakasama, Samart, Somtawin Sirireung, Bandit Thinkhamrop, Nongnuch Sirachainan, and Suradej Hongeng. "Efficacy of Deferasirox on Iron Chelation in Thalassemia Patients After Hematopoietic Stem Cell Transplantation." Blood 118, no. 21 (November 18, 2011): 3136. http://dx.doi.org/10.1182/blood.v118.21.3136.3136.
Повний текст джерелаАнотація:
Abstract Abstract 3136 Background Severe b thalassemia disease can be cured by hematopoietic stem cell transplantation (HSCT). Iron overload is one of the complications after HSCT in these patients. To prevent further tissue damages from excessive iron in the body, iron chelation is recommended in ex-thalassemics. Phlebotomy is an effective procedure removing iron excess in post HSCT thalassemia patients. However, the limitations of phlebotomy exist including young children, difficult access to peripheral veins, mixed chimerism, and non-compliance. Deferasirox has been shown to be an effectively oral iron chelator in transfusion-dependent thalassemia patients. The efficacy of deferasirox on iron removal in post HSCT survivors is limited. Objective To compare the efficacy of iron chelation between deferasirox and phlebotomy in post HSCT thalassemia patients Methods We included patients with severe b thalassemia who had received related or unrelated donor HSCT at least one year. The patients had no evidence of chronic GVHD or taking immunosuppressive agent at least 6 months. Twenty four patients were randomized into deferasirox or phlebotomy arm (12 patients each). The patients in deferasirox arm received deferasirox starting at the dose of 20 mg/kg/day. Adverse drug reactions were recorded. The dose of deferasirox was adjusted if severe side effects were recognized. The patients in phlebotomy arm underwent monthly 10 mL/kg blood withdrawal with normal saline replacement. Symptoms of hypotension and blood pressure were monitored during the procedure. Laboratory investigations including CBC, LFT, BUN, creatinine, and urinalysis were determined every month. Serum iron, total iron binding capacity and ferritin were measured every 3 months. Results The median age, M :F, types of thalassemia, and severity class were not different between two groups. In deferasirox group, the median dose of deferasirox was 18.9 mg/kg/day (range, 10 – 21.6 mg/kg). Two patients had reduced deferasirox dosage due to rising creatinine and GI symptoms. The baseline median (range) of alanine transaminase (ALT), transferrin saturation (TS), and ferritin were 68 U/L (14 – 332 U/L), 87.9% (35.6 – 106.1%), and 2, 802.9 (1, 332 – 6, 628.4 mg/dL) in deferasirox group and 53.5 U/L (32 – 78 U/L), 70.9 % (36.5 – 96.6%), and 1, 740 (1, 246.4 – 5, 780 mg/dL) in phlebotomy group. The 12-month median (range) of ALT, TS, and ferritin were 37.5 (12 – 508 U/L), 39.5% (28.3 – 70.6%), and 1, 743.5 mg/dL (721.1 – 3555.9 mg/dL) in deferasirox group and 40.5 U/L (27 – 97), 39.2% (22.2 – 95.2%), and 896.2 mg/dL (345.1 – 3, 740 mg/dL) in phlebotomy group. The median changes of ALT, TS, and ferritin at 12-month from baseline of these two groups were not different (Table 1). Conclusion Deferasirox was well tolerated and had manageable side effects in ex-thalassemics. Deferasirox reduced serum ferritin as effectively as phlebotomy in thalassemia patients after HSCT. Disclosures: No relevant conflicts of interest to declare.
8
Vuong, Lan N., Toan D. Pham, Khanh T. Q. Le, Trung T. Ly, Ho L. Le, Diem T. N. Nguyen, Vu N. A. Ho, et al. "Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study." Human Reproduction 36, no. 7 (April 30, 2021): 1821–31. http://dx.doi.org/10.1093/humrep/deab093.
Повний текст джерелаАнотація:
Abstract STUDY QUESTION Does the addition of oral dydrogesterone to vaginal progesterone as luteal phase support improve pregnancy outcomes during frozen embryo transfer (FET) cycles compared with vaginal progesterone alone? SUMMARY ANSWER Luteal phase support with oral dydrogesterone added to vaginal progesterone had a higher live birth rate and lower miscarriage rate compared with vaginal progesterone alone. WHAT IS KNOWN ALREADY Progesterone is an important hormone that triggers secretory transformation of the endometrium to allow implantation of the embryo. During IVF, exogenous progesterone is administered for luteal phase support. However, there is wide inter-individual variation in absorption of progesterone via the vaginal wall. Oral dydrogesterone is effective and well tolerated when used to provide luteal phase support after fresh embryo transfer. However, there are currently no data on the effectiveness of luteal phase support with the combination of dydrogesterone with vaginal micronized progesterone compared with vaginal micronized progesterone after FET. STUDY DESIGN, SIZE, DURATION Prospective cohort study conducted at an academic infertility center in Vietnam from 26 June 2019 to 30 March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS We studied 1364 women undergoing IVF with FET. Luteal support was started when endometrial thickness reached ≥8 mm. The luteal support regimen was either vaginal micronized progesterone 400 mg twice daily plus oral dydrogesterone 10 mg twice daily (second part of the study) or vaginal micronized progesterone 400 mg twice daily (first 4 months of the study). In women with a positive pregnancy test, the appropriate luteal phase support regimen was continued until 7 weeks’ gestation. The primary endpoint was live birth after the first FET of the started cycle, with miscarriage <12 weeks as one of the secondary endpoints. MAIN RESULTS AND THE ROLE OF CHANCE The vaginal progesterone + dydrogesterone group and vaginal progesterone groups included 732 and 632 participants, respectively. Live birth rates were 46.3% versus 41.3%, respectively (rate ratio [RR] 1.12, 95% CI 0.99–1.27, P = 0.06; multivariate analysis RR 1.30 (95% CI 1.01–1.68), P = 0.042), with a statistically significant lower rate of miscarriage at <12 weeks in the progesterone + dydrogesterone versus progesterone group (3.4% versus 6.6%; RR 0.51, 95% CI 0.32–0.83; P = 0.009). Birth weight of both singletons (2971.0 ± 628.4 versus 3118.8 ± 559.2 g; P = 0.004) and twins (2175.5 ± 494.8 versus 2494.2 ± 584.7; P = 0.002) was significantly lower in the progesterone plus dydrogesterone versus progesterone group. LIMITATIONS, REASONS FOR CAUTION The main limitations of the study were the open-label design and the non-randomized nature of the sequential administration of study treatments. However, our systematic comparison of the two strategies was able to be performed much more rapidly than a conventional randomized controlled trial. In addition, the single ethnicity population limits external generalizability. WIDER IMPLICATIONS OF THE FINDINGS Our findings study suggest a role for oral dydrogesterone in addition to vaginal progesterone as luteal phase support in FET cycles to reduce the miscarriage rate and improve the live birth rate. Carefully planned prospective cohort studies with limited bias could be used as an alternative to randomized controlled clinical trials to inform clinical practice. STUDY FUNDING/COMPETING INTERESTS This study received no external funding. LNV has received speaker and conference fees from Merck, grant, speaker and conference fees from Merck Sharpe and Dohme, and speaker, conference and scientific board fees from Ferring; TMH has received speaker fees from Merck, Merck Sharp and Dohme, and Ferring; R.J.N. has received scientific board fees from Ferring and receives grant funding from the National Health and Medical Research Council (NHMRC) of Australia; BWM has acted as a paid consultant to Merck, ObsEva and Guerbet, and is the recipient of grant money from an NHMRC Investigator Grant. TRIAL REGISTRATION NUMBER NCT0399876.
9
Sengupta, Amitava, and Jose Cancelas. "Leukemic Stem Cells and Progenitors Demonstrate Impaired Interaction with the Hematopoietic Microenvironment in Vivo in An Inducible Murine Model of Chronic Myelogenous Leukemia." Blood 112, no. 11 (November 16, 2008): 191. http://dx.doi.org/10.1182/blood.v112.11.191.191.
Повний текст джерелаАнотація:
Abstract Chronic myelogenous leukemia (CML) is a stem cell malignancy induced by p210 BCR-ABL and characterized by myeloproliferation in BM and egression of leukemic stem cells and progenitors (LSC/P) to extramedullary sites. Persistence of BCR-ABL+ HSC in patients under Imatinib suggests inhibition of ABL-kinase alone is not sufficient to eliminate the LSC/P. One of the major hallmarks of CML induced by signaling downstream BCR-ABL is the loss of control of the hematopoietic microenvironment on LSC/P. Expression of p210 BCR-ABL has been associated with loss of adhesion to the bone marrow, impaired migration in response to CXCL12 and decreased retention in the BM. In order to study the putative LSC/P niches in steady-state chronic-phase leukemia, we have analyzed the ability of LSC/P to proliferate and get retained in the bone marrow (BM) in an inducible model of CML. Binary transgenic SCL-tTA/TRE-BCR-ABL mice (Koschmieder S et al., Blood 2005) express p210 BCR-ABL in LSC/P upon doxycycline withdrawal (CML mice). Induced myeloproliferation was associated with activation of the downstream signaling effectors CrkL and p38-MAPK and expansion of circulating (Table 1) and splenic LSC/P but not in BM, suggesting massive LSC/P egression from the marrow (Table 2). Proliferation analysis showed that myeloid expansion in the spleen was secondary to increased cycling of Lin−Sca1+c-Kit+ (LSK) cells (3.1-fold increase in S-phase cells, P<0.05), but not in Lin−/c-Kit+ (LK) population, compared with the control spleens. In agreement with the LSC/P BM content data, the frequency of BM-derived LSK and LK cells incorporating BrdU in CML and in control mice remained similar, suggesting a specific egression of LSC/P from the BM to extramedullary sites. To test whether this model truly represented a model of BM LSC/P egression, we compared the splenic and BM LSC/P compared with their controls regarding their adhesion molecule expression, interaction with the hematopoietic microenvironment (HM) and homing to the overall marrow cavity and endosteal space. Splenic, but not BM-derived, LSK and LSK CD34+ ST-HSCs had increased cell surface expression of CD44 compared to controls (1.35 fold, P=0.006 and 1.23 fold, P<0.05 respectively) and decreased expression of L-selectin (8.7 fold, P<0.05) while expression of CXCR4, α4β1 and α5β1 integrins remain similar in bone marrow and splenocytes from CML and control mice. CML BM progenitors also showed 18-fold reduced adhesion to fibronectin and 1.4-fold increased migration towards CXCL12 compared to control BM progenitors. Myeloproliferative disease was transplantable into non-transgenic littermates and homing of CML BM progenitors was increased (4.3 fold, P<0.005) in myeloablated littermate recipient BM. However, lineage-negative leukemic BM-derived cells which had increased homing in BM of recipient mice had an impaired ability to migrate to the BM endosteal space compared with their littermate controls (control: 31 ± 18% vs CML mice: 17.6 ± 17%), suggesting an specific impairment to lodge in specialized anatomically-defined hematopoietic “niches”. Altogether, this murine model may represent an adequate in vivo system to analyze the ability of p210 BCR-ABL-expressing LSC/P to interact with BM niches and study the control of the hematopoietic microenvironment on LSC/P survival, proliferation and retention. Table 1 Increase in circulating LSC/P in the CML mice after withdrawal of doxycyclin Peripheral Blood LSK (×103)Cells/mL Blood P<0.05 LT-HSC(×103)Cells/mL Blood P<0.05 CFU-GM+BFU-E/mL Blood P<0.05 Control 1.56 ± 0.25 0.459 ± 0.29 60.86 ± 51.09 CML mice 3.56 ± 1.52 2.159 ± 2.03 869.6 ± 628.4 Table 2. Immunophenotypic analysis of BM and splenocytes in control and CML mice Population BM (Cells ×104) (Control) BM (Cells x104) (CML) SP (Cells ×104) (Control) SP (Cells x104) (CML) C-Kit + Sca1 + 24.3 ± 9.9 21.3 ± 11 6.8 ± 4.5 30.1 ± 12.3 (P<0.05) Mac1 + Gr1 + 1779 ± 307 1583 ± 265 78.4 ± 32 608 ± 377 (P<0.05) CFU-C/10 5 Cells 342 ± 66 334 ± 99 63.3 ± 7.09 79 ± 6.54 (P<0.05)
10
Gaudreault, Nathalie, Nikit Kumar, Jessica Possada, and Robert Raffai. "Apolipoprotein E Suppresses Atherosclerosis by Reducing Leukocyte Recruitment to Atheroma." FASEB Journal 24, S1 (April 2010). http://dx.doi.org/10.1096/fasebj.24.1_supplement.628.4.
Повний текст джерела
11
Rebelo, Fernanda, Thatiana Pinto, Dayana Farias, Jaqueline Lepsch, Juliana Vaz, and Gilberto Kac. "Maternal serum n‐6 polyunsaturated fatty acids are related to blood pressure during pregnancy: results from a prospective cohort from Rio de Janeiro, Brazil (628.4)." FASEB Journal 28, S1 (April 2014). http://dx.doi.org/10.1096/fasebj.28.1_supplement.628.4.
Повний текст джерела
12
Sandoval, Efren G., Michelle T. Juarez, and William McGinnis. "Effects on Epidermal Actin Composition in Wounded Drosophila Grainy head Zygotic Mutants." FASEB Journal 22, S1 (March 2008). http://dx.doi.org/10.1096/fasebj.22.1_supplement.628.4.
Повний текст джерела
13
Filaretova, Ludmila, Tatiana Bagaeva, and Natalia Yarushkina. "Regulation of Somatic Pain Sensitivity under the Circumstances of Indometacin‐InducedGastric Injury: Participation of Cortricotropin‐Releasing Factor." FASEB Journal 29, S1 (April 2015). http://dx.doi.org/10.1096/fasebj.29.1_supplement.628.4.
Повний текст джерела
14
Jonkam, Collette, Yong Zhu, Daniel Traber, Kamna Bansal, Sebastian Rehberg, Linda Sousse, Lillian Traber, and Perenlei Enkhbaatar. "The relationship between cardiovascular collapse in Methicillin‐resistant Staphylococcus aureus‐induced sepsis and excessive expression of reactive nitrogen and oxidative species." FASEB Journal 23, S1 (April 2009). http://dx.doi.org/10.1096/fasebj.23.1_supplement.628.4.
Повний текст джерела
15
Zhao, Jingru, Brandy Wade, Jing Ma, Charles Michael Hart, and Roy Sutliff. "Differential Ubiquitination of Profilin‐1 in Hypoxia‐Induced Pulmonary Hypertension." FASEB Journal 32, S1 (April 2018). http://dx.doi.org/10.1096/fasebj.2018.32.1_supplement.628.4.
Повний текст джерела
16
Walker, Sarah E., Xiaozhuo E. Liu, and Houtan E. Moshiri. "Binding to the ribosome by eIF4B drives yeast translational control in response to membrane stressors." FASEB Journal 33, S1 (April 2019). http://dx.doi.org/10.1096/fasebj.2019.33.1_supplement.628.4.
Повний текст джерела
17
Sommakia, Salah, Naredos H. Almaw, Sandra H. Lee, Dinesh K. A. Ramadurai, Iosif Taleb, Christos P. Kyriakopoulos, Chris J. Stubben, et al. "FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure." Circulation: Heart Failure 15, no. 3 (March 2022). http://dx.doi.org/10.1161/circheartfailure.121.008910.
Повний текст джерелаАнотація:
Background: Extrinsic control of cardiomyocyte metabolism is poorly understood in heart failure (HF). FGF21 (Fibroblast growth factor 21), a hormonal regulator of metabolism produced mainly in the liver and adipose tissue, is a prime candidate for such signaling. Methods: To investigate this further, we examined blood and tissue obtained from human subjects with end-stage HF with reduced ejection fraction at the time of left ventricular assist device implantation and correlated serum FGF21 levels with cardiac gene expression, immunohistochemistry, and clinical parameters. Results: Circulating FGF21 levels were substantially elevated in HF with reduced ejection fraction, compared with healthy subjects (HF with reduced ejection fraction: 834.4 [95% CI, 628.4–1040.3] pg/mL, n=40; controls: 146.0 [86.3–205.7] pg/mL, n=20, P =1.9×10 −5 ). There was clear FGF21 staining in diseased cardiomyocytes, and circulating FGF21 levels negatively correlated with the expression of cardiac genes involved in ketone metabolism, consistent with cardiac FGF21 signaling. FGF21 gene expression was very low in failing and nonfailing hearts, suggesting extracardiac production of the circulating hormone. Circulating FGF21 levels were correlated with BNP (B-type natriuretic peptide) and total bilirubin, markers of chronic cardiac and hepatic congestion. Conclusions: Circulating FGF21 levels are elevated in HF with reduced ejection fraction and appear to bind to the heart. The liver is likely the main extracardiac source. This supports a model of hepatic FGF21 communication to diseased cardiomyocytes, defining a potential cardiohepatic signaling circuit in human HF.
18
Ho, T., T. Pham, K. Le, T. Ly, H. Le, D. Nguyen, V. Ho, et al. "O-233 Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles: a prospective cohort study." Human Reproduction 36, Supplement_1 (July 1, 2021). http://dx.doi.org/10.1093/humrep/deab128.057.
Повний текст джерелаАнотація:
Abstract Study question Does the addition of oral dydrogesterone to vaginal progesterone as luteal phase support improve pregnancy outcomes during frozen embryo transfer (FET) cycles compared with vaginal progesterone alone? Summary answer Luteal phase support with oral dydrogesterone added to vaginal progesterone improves live birth rates and reduces miscarriage rates compared with vaginal progesterone alone. What is known already Progesterone is an important hormone that triggers secretory transformation of the endometrium to allow implantation of the embryo. During in vitro fertilization (IVF), exogenous progesterone is administered for luteal phase support. However, there is wide inter-individual variation in absorption of progesterone via the vaginal wall. Oral dydrogesterone is effective and well tolerated when used to provide luteal phase support after fresh embryo transfer. However, there are currently no data on the effectiveness of luteal phase support with the combination of dydrogesterone with vaginal micronized progesterone compared with vaginal micronized progesterone after FET. Study design, size, duration Prospective cohort study conducted at an academic infertility center in Vietnam from 26 June 2019 to 30 March 2020. Participants/materials, setting, methods We studied 1364 women undergoing IVF with FET. The luteal support regimen was either vaginal micronized progesterone 400 mg twice daily plus oral dydrogesterone 10 mg twice daily (second part of the study) or vaginal micronized progesterone 400 mg twice daily (first 4 months of the study). The primary endpoint was live birth after the first FET of the started cycle, with miscarriage <12 weeks as one of the secondary endpoints. Main results and the role of chance The vaginal progesterone + dydrogesterone group and vaginal progesterone groups included 732 and 632 participants, respectively. Live birth rates were 46.3% versus 41.3%, respectively (rate ratio [RR] 1.12, 95% confidence interval [CI] 0.99–1.27, p = 0.06; multivariate analysis RR 1.30 (95% CI 1.01–1.68), p = 0.042), with a statistically significant lower rate of miscarriage at < 12 weeks (3.4% vs 6.6%; RR 0.51, 95% CI 0.32–0.83; p = 0.009). Birth weight of both singletons (2971.0 ± 628.4 vs. 3118.8 ± 559.2 g; p = 0.004) and twins (2175.5 ± 494.8 vs. 2494.2 ± 584.7; p = 0.002) was significantly lower in the progesterone plus dydrogesterone versus progesterone group. Limitations, reasons for caution The study were the open-label design and the non-randomized nature of the sequential administration of study treatments. However, our systematic comparison of the two strategies was able to be performed much more rapidly than a conventional randomized controlled trial. In addition, the single ethnicity population limits external generalizability. Wider implications of the findings Oral dydrogesterone in addition to vaginal progesterone as luteal phase support in FET cycles can reduce the miscarriage rate and improve the live birth rate. Carefully planned prospective cohort studies with limited bias could be used as an alternative to randomized controlled clinical trials to inform clinical practice. Trial registration number NCT03998761